Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anrikefon (HSK21542) for Postoperative Pain in Abdominal Surgery
NCT05390905Phase 3Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Jun 2022
- Primary completion
- Dec 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hsk21542 in postoperative pain, sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoints: Sum of Pain Intensity Differences (SPID) in the HSK21542 group and the placebo group at 24 hours, Sum of Pain Intensity Differences (SPID) in tramadol group and the placebo group at 24 hours and 1 more. Started Jun 2022; status: completed.
02
Drugs
hsk21542
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT05390905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05390905.